ondansetron has been researched along with Muscular Weakness in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy." | 5.20 | [Optimization of pharmacological therapy for weakness syndrome in incurable patients]. ( Glushchenko, VA; Karitsky, AP; Kvashnin, AV; Rozengard, SA; Ryazankina, AA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryazankina, AA | 1 |
| Rozengard, SA | 1 |
| Glushchenko, VA | 1 |
| Karitsky, AP | 1 |
| Kvashnin, AV | 1 |
1 trial available for ondansetron and Muscular Weakness
| Article | Year |
|---|---|
[Optimization of pharmacological therapy for weakness syndrome in incurable patients].
Topics: Acetamides; Adamantane; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2015 |